MORF-057 IR Capsule
Sponsors
Morphic Therapeutic Inc.
Conditions
Moderately to Severely Active Crohn’s DiseaseModerately to severely active ulcerative colitis
Phase 2
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2)
Active, not recruitingCTIS2022-500953-17-00
Start: 2023-03-23Target: 172Updated: 2025-12-11
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 2 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease (GARNET)
RecruitingCTIS2023-508158-24-00
Start: 2024-06-25Target: 150Updated: 2025-12-02